In my case, partly because my daughter is a GP, probably because of her input we received a lot more information than most patients. Because of my condition, endocarditis and a growth on the valve, a surgical procedure was opted for in preference to TAVR. The cardiac team informed me that the valve should last 10-20 years before requiring replacement. At a point where it does deteriorate sufficiently to require replacement a TAVR procedure, valve in valve, is the most likely option. Regular echos monitor the valves performance.
I've attached a peer reviewed paper to support my comments. Again, please correct me if I've posted anything untrue.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994436/
In my case, partly because my daughter is a GP, probably because...
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.75 |
Change
-0.230(1.21%) |
Mkt cap ! $360.4M | |||
| Open | High | Low | Value | Volume |
| $19.00 | $19.00 | $18.52 | $179.2K | 9.566K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 109 | $18.51 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.75 | 999 | 1 |
View Market Depth
| Last trade - 16.10pm 30/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$18.52 |
Change
-0.230 ( 2.01 %) |
||||
| Open | High | Low | Volume | ||
| $18.52 | $18.52 | $18.52 | 14 | ||
| Last updated 10.49am 30/05/2024 ? | |||||
| AVR (ASX) Chart |